Welcome to our dedicated page for Vivani Medical news (Ticker: VANI), a resource for investors and traders seeking the latest updates and insights on Vivani Medical stock.
Vivani Medical, Inc. (Nasdaq: VANI) is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants based on its NanoPortal™ platform, along with neuromodulation devices through its Cortigent subsidiary. The VANI news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how Vivani’s clinical programs, financings, and corporate actions evolve over time.
Recent Vivani news has highlighted progress with NPM-139, a semaglutide GLP-1 implant program for chronic weight management, including plans for a Phase 1 clinical study and preparations for a potential Phase 2 dose-ranging trial, subject to regulatory clearance and supportive data. The company has also reported results from the LIBERATE-1 Phase 1 study of its exenatide implant NPM-115, which it describes as the first-in-human application of the NanoPortal technology, as well as preclinical data suggesting sustained weight loss from a single NPM-139 implant in ongoing studies.
In addition to R&D updates, Vivani’s news flow includes announcements of equity financings, such as private placements and a registered direct offering of common stock, with stated use of proceeds for research, clinical development, working capital and general corporate purposes. The company also issues news about its proposed spin-off of Cortigent, Inc., which develops brain implant devices like the Orion® visual cortical prosthesis system and a stroke recovery neurostimulation platform.
Investors and followers of VANI can use this page to monitor clinical milestones, capital-raising transactions, conference presentations, and key steps in the Cortigent spin-off process, all drawn from Vivani’s own press releases and related regulatory communications.
Vivani Medical (NASDAQ: VANI) announced its CEO Adam Mendelsohn's upcoming participation in the American Association of Pharmaceutical Scientists' virtual workshop "Beyond GLP1s: Where the Science will Take Business Next" on May 13-14, 2025. Dr. Mendelsohn will present on "Addressing Patient Adherence: Advances in Drug Delivery" on May 14 at 11:15 am ET, focusing on Vivani's miniature drug implants and their proprietary NanoPortal™ technology.
The company's lead program, NPM-115, is a six-month GLP-1 (exenatide) implant for weight management, with results from the LIBERATE-1™ human study expected this year. Dr. Mendelsohn will also participate in a panel discussion at 2:00 pm ET about key hurdles and trends in GLP-1 drug class development.
Vivani Medical (NASDAQ: VANI) has announced its participation in a virtual fireside chat hosted by H.C. Wainwright & Company on April 24, 2025, at 10 a.m. Eastern Time. The presentation will feature CEO Adam Mendelsohn, Ph.D., and CMO Lisa Porter, M.D., who will discuss the company's LIBERATE-1 clinical trial.
The discussion will focus on NPM-115, Vivani's innovative miniature, twice-yearly GLP-1 (exenatide) implant being developed for chronic weight management. The company is currently conducting LIBERATE-1 as a first-in-human study, with topline data expected in mid-year 2025.
Vivani specializes in developing miniature, ultra long-acting drug implants, with a portfolio focusing on once or twice-yearly GLP-1 implants for both chronic weight management and type 2 diabetes treatment.
Vivani Medical (NASDAQ: VANI) and Okava Pharmaceuticals have expanded their collaboration to develop OKV-119, a long-acting GLP-1 therapy for dogs, targeting weight management, diabetes, and cardiometabolic conditions. The therapy utilizes Vivani's NanoPortal™ technology to deliver therapeutic molecules over extended periods from a single implant.
The collaboration, initially focused on cats since 2019, now addresses a critical need as over 50% of U.S. dogs are overweight or obese. OKV-119 aims to provide dosing every six months or longer, mimicking the physiological effects of fasting without disrupting feeding routines. Research indicates leaner dogs can live more than two years longer than heavier ones.
The expanded partnership maintains minimal costs and risks for Vivani while offering potential upside through future milestone payments and royalties. The financial terms of the agreement were not disclosed.
Vivani Medical (NASDAQ: VANI) reported its Q4 and full year 2024 results, highlighting significant progress in its drug implant programs. The company successfully completed enrollment in its LIBERATE-1™ first-in-human study of NPM-115 (exenatide implant), with top-line data expected in mid-2025.
Key developments include positive preclinical weight loss data for NPM-139 (semaglutide implant), showing comparable results to Ozempic®/Wegovy® injections with potential for once-yearly dosing. The company secured $8.25M in equity financing, extending operations into Q2 2026.
Financial highlights for 2024:
- Cash position: $19.7M as of December 31, 2024
- Net loss: $23.5M, improved from $25.7M in 2023
- R&D expenses: $15.7M, down 7% from 2023
- G&A expenses: $8.9M, decreased 11% from 2023
The company plans to spin off its Cortigent subsidiary, which develops brain implant devices, to focus on its drug implant pipeline for chronic diseases.
Vivani Medical (NASDAQ: VANI) has secured an $8.25 million private placement equity financing through the sale of 7,366,071 shares at $1.12 per share. The financing was arranged with an entity owned by Gregg Williams, the Company's board chairman.
The funding will extend the company's cash runway into Q2 2026 and accelerate the development of two key products:
- NPM-139: A once or twice-yearly GLP-1 (semaglutide) implant for chronic weight management
- NPM-115: A twice-yearly GLP-1 (exenatide) implant for chronic weight management
The private placement was priced 'at-the-market' under Nasdaq rules and will have multiple closing dates. The securities being sold have not been registered under the Securities Act of 1933.
Vivani Medical (NASDAQ: VANI) has announced promising preclinical data for NPM-139, its subdermal semaglutide implant for chronic weight management. The implant, utilizing their proprietary NanoPortal™ technology, demonstrated nearly 20% placebo-adjusted weight loss from a single administration in healthy rats over a 91-day treatment period.
The technology successfully delivers semaglutide (active ingredient in Ozempic®/Wegovy®) with potential for once or twice-yearly dosing. NPM-139 has shown therapeutic semaglutide exposure levels over six months in healthy rats, with in vitro stability measurements indicating potential for once-yearly administration.
The company's ongoing LIBERATE-1 clinical study for NPM-115 (exenatide implant) is progressing, with top-line data expected by mid-2025. This study will provide critical information for both NPM-115 and NPM-139 development, representing the first human application of NanoPortal technology.
Vivani Medical (NASDAQ: VANI), a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting drug implants, has announced its participation in the upcoming Emerging Growth Conference on March 27, 2025.
Company President and CEO Adam Mendelsohn, Ph.D. will deliver a 30-minute presentation starting at 2:20 pm Eastern Time. The interactive session will include a company overview and a potential Q&A segment, providing individual and institutional investors, advisors, and analysts the opportunity to engage directly with management.
Investors can submit questions in advance to Questions@EmergingGrowth.com. The presentation will be archived and available on EmergingGrowth.com and the Emerging Growth YouTube channel post-conference.
Vivani Medical (NASDAQ: VANI) has announced two significant milestones in its LIBERATE-1™ clinical trial: the successful first implant of its NPM-115 GLP-1 (exenatide) implant and full enrollment of 24 subjects within four weeks. The miniature, twice-yearly implant is being developed for chronic weight management.
The NPM-115 implant has shown comparable preclinical weight loss results to semaglutide injections (Ozempic®/Wegovy®). The first implant administration was well-tolerated, and top-line study results are expected in mid-2025.
The company's NanoPortal™ platform technology aims to address medication adherence challenges, as approximately 50% of patients regularly miss doses. The LIBERATE-1 study will explore NPM-115's pharmacokinetic profile, which has demonstrated consistent and minimally fluctuating drug release in preclinical studies. The implant could potentially be used for treating type 2 diabetes and other conditions where GLP-1 treatment shows clinical benefit.
Vivani Medical (NASDAQ: VANI) has announced plans to spin off its Cortigent neurostimulation business as an independent publicly-traded company. The spin-off, expected to complete by Q3 2025, aims to create two focused companies dedicated to their respective therapeutic areas.
Cortigent specializes in brain implant devices and is known for developing the Orion® artificial vision system and the FDA-authorized Argus® II Retinal Prosthesis System. The company recently completed a 6-year clinical study for Orion in 2024, showing promising safety and efficacy results. The technology is also being developed for recovery of arm and hand motion in stroke-related paralysis.
Post spin-off, Vivani will focus exclusively on developing miniature, ultra long-acting GLP-1 implants for chronic weight management and type 2 diabetes with once or twice-yearly administration. The transaction is intended to be tax-free for U.S. federal income tax purposes, with Vivani stockholders receiving shares in the new company.
Vivani Medical (NASDAQ: VANI) has initiated its first-in-human clinical trial, LIBERATE-1™, testing a novel GLP-1 (exenatide) implant for obesity and overweight treatment at two Australian centers. The trial marks the first clinical application of their proprietary NanoPortal™ drug implant technology, designed to provide comparable efficacy to semaglutide with twice-yearly administration.
The randomized trial will evaluate safety, tolerability, and pharmacokinetics in participants who will first undergo 8 weeks of semaglutide titration before being randomized into three groups: exenatide implant (n=8), weekly exenatide injections (n=8), or weekly semaglutide injections (n=8) for 9 weeks. Top-line data is expected in mid-2025.